Effects of targeted-edited oncogenic insulin-like growth factor-1 receptor with specific-sgRNA on biological behaviors of HepG2 cells

Table 4 Edited IGF-1R increasing HepG2 cell sensitivity to anti-cancer drugs

Group	Control	Neg-sgRNA	Sg-IGF1R2	F value	q value1	P value
Sorafenib
0.0 nmol/L	0.297 ± 0.06	0.310 ± 0.07	0.199 ± 0.07	1.361	2.604	0.026
2.5 nmol/L	0.326 ± 0.10	0.335 ± 0.11	0.188 ± 0.05	100.00	3.364	0.007
5.0 nmol/L	0.337 ± 0.11	0.318 ± 0.05	0.191 ± 0.06	3.316	2.854	0.017
10.0 nmol/L	0.331 ± 0.05	0.284 ± 0.17	0.152 ± 0.09	1.494	3.085	0.012
20.0 nmol/L	0.093 ± 0.03	0.084 ± 0.02	0.033 ± 0.04	6.499	0.464	0.009
Oxaliplation
0.0 μmol/L	2.391 ± 0.30	2.351 ± 0.17	1.429 ± 0.27	51.91	0.874	0.001
5.0 μmol/L	1.064 ± 0.21	1.014 ± 0.05	0.677 ± 0.08	6.891	4.218	0.002
10.0 μmol/L	0.659 ± 0.16	0.575 ± 0.13	0.417 ± 0.14	1.515	2.768	0.020
20.0 μmol/L	0.288 ± 0.12	0.280 ± 0.08	0.148 ± 0.08	36.000	2.819	0.018
40.0 μmol/L	0.164 ± 0.05	0.162 ± 0.07	0.099 ± 0.04	1.000	2.815	0.018

¹Compared with the control group (n = 6).